Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.
Article CAS PubMed Google Scholar
Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24:1357–66.
Article CAS PubMed PubMed Central Google Scholar
Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2021;21(1): 102925.
Skaggs BJ, Grossman J, Sahakian L, Perry L, FitzGerald J, Charles-Schoeman C, et al. A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol. 2021;3:209–20.
Article PubMed PubMed Central Google Scholar
Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996–2011. Arthritis Care Res (Hoboken). 2015;67:1078–85.
Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521–30.
Article CAS PubMed Google Scholar
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640–4.
Article CAS PubMed Google Scholar
Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387:611–7.
Article CAS PubMed Google Scholar
Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1β, TNF-α, and LPS. J Leukoc Biol. 2000;67:577–84.
Article CAS PubMed Google Scholar
Hirose S, Lin Q, Ohtsuji M, Nishimura H, Verbeek JS. Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int Immunol. 2019;31:687–96.
Article CAS PubMed PubMed Central Google Scholar
Qiu F, Li Y, Zhu Y, Li G, Lei F, Zhang S, et al. CX3CR1 might be a promising predictor of systemic lupus erythematosus patients with pulmonary fibrosis. Scand J Immunol. 2021;94: e13038.
Article CAS PubMed Google Scholar
Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670–5.
Article CAS PubMed Google Scholar
Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int. 2002;62:488–95.
Article CAS PubMed Google Scholar
Nakatani K, Yoshimoto S, Iwano M, Asai O, Samejima K, Sakan H, et al. Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am J Physiol Renal Physiol. 2010;299:F207–16.
Article CAS PubMed Google Scholar
Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 2005;52:1522–33.
Article CAS PubMed Google Scholar
Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, et al. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int. 1999;56:612–20.
Article CAS PubMed Google Scholar
Liao X, Ren J, Reihl A, Pirapakaran T, Sreekumar B, Cecere TE, et al. Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses. Clin Exp Immunol. 2017. https://doi.org/10.1111/cei.13017.
Article PubMed PubMed Central Google Scholar
Hochheiser K, Heuser C, Krause TA, Teteris S, Ilias A, Weisheit C, et al. Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression. J Clin Invest. 2013;123:4242–54.
Article CAS PubMed PubMed Central Google Scholar
Liu F, Dai S, Feng D, Qin Z, Peng X, Sakamuri S, et al. Distinct fate, dynamics and niches of renal macrophages of bone marrow or embryonic origins. Nat Commun. 2020;11:2280.
Article CAS PubMed PubMed Central Google Scholar
Cormican S, Griffin MD. Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease? Front Immunol. 2021;12: 664202.
Article CAS PubMed PubMed Central Google Scholar
Grone HJ, Cohen CD, Grone E, Schmidt C, Kretzler M, Schlondorff D, et al. Spatial and temporally restricted expression of chemokines and chemokine receptors in the developing human kidney. J Am Soc Nephrol. 2002;13:957–67.
Article CAS PubMed Google Scholar
Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963–72.
Article CAS PubMed Google Scholar
McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111:1241–50.
Article CAS PubMed PubMed Central Google Scholar
Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med. 2010;16:1305–12.
Article CAS PubMed Google Scholar
Bonacina F, Martini E, Svecla M, Nour J, Cremonesi M, Beretta G, et al. Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Cardiovasc Res. 2021;117:2069–82.
Article CAS PubMed Google Scholar
Dong L, Nordlohne J, Ge S, Hertel B, Melk A, Rong S, et al. T cell CX3CR1 mediates excess atherosclerotic inflammation in renal impairment. J Am Soc Nephrol. 2016;27:1753–64.
Article CAS PubMed Google Scholar
Dagkalis A, Wallace C, Hing B, Liversidge J, Crane IJ. CX3CR1-deficiency is associated with increased severity of disease in experimental autoimmune uveitis. Immunology. 2009;128:25–33.
Article CAS PubMed PubMed Central Google Scholar
Beli E, Dominguez JM 2nd, Hu P, Thinschmidt JS, Caballero S, Li Calzi S, et al. CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes. J Mol Med (Berl). 2016;94:1255–65.
Article CAS PubMed Google Scholar
Kawamura N, Katsuura G, Yamada-Goto N, Novianti E, Inui A, Asakawa A. Reduced brain fractalkine-CX3CR1 signaling is involved in the impaired cognition of streptozotocin-treated mice. IBRO Rep. 2020;9:233–40.
Article PubMed PubMed Central Google Scholar
Mai W, Liu X, Wang J, Zheng J, Wang X, Zhou W. Protective effects of CX3CR1 on autoimmune inflammation in a chronic EAE model for MS through modulation of antigen-presenting cell-related molecular MHC-II and its regulators. Neurol Sci. 2019;40:779–91.
Ridderstad Wollberg A, Ericsson-Dahlstrand A, Jureus A, Ekerot P, Simon S, Nilsson M, et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Proc Natl Acad Sci USA. 2014;111:5409–14.
Article PubMed PubMed Central Google Scholar
Yadav AK, Kumar V, Jha V. Association of chemokine receptor CX3CR1 V249I and T280M polymorphisms with chronic kidney disease. Indian J Nephrol. 2016;26:275–9.
Article CAS PubMed PubMed Central Google Scholar
De Lema GP, Lucio-Cazaña FJ, Molina ANA, Luckow B, Schmid H, de Wit C, et al. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int. 2004;66:1018–28.
Zhang H, Liao X, Sparks JB, Luo XM, Schloss PD. Dynamics of gut microbiota in autoimmune lupus. Appl Environ Microbiol. 2014;80:7551–60.
Article PubMed PubMed Central Google Scholar
Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, et al. Control of lupus nephritis by changes of gut microbiota. Microbiome. 2017;5:73.
留言 (0)